The financial services giant Cantor Fitzgerald is predicting the stock market will see rallies in the next one to two weeks.

Cantor Fitzgerald analyst K. Kluska now expects that the biotechnology company will post earnings per share of ($0.60) for the year, down from their prior estimate of ($0.49). Skip to main content ...

Exagen Inc. (NASDAQ:XGN – Free Report) – Equities researchers at Cantor Fitzgerald reduced their FY2025 earnings per share estimates for Exagen in a research note issued on Wednesday ...

Cantor Fitzgerald analyst P. Stavropoulos now expects that the company will post earnings per share of ($2.03) for the year, up from their previous forecast of ($2.20). Cantor Fitzgerald currently ...

Cantor Fitzgerald reaffirmed their overweight rating on shares of EVE (NYSE:EVEX – Free Report) in a research note released on Friday morning,Benzinga reports. They currently have a $5.00 target ...

Nova (NASDAQ:NVMI – Get Free Report) had its target price decreased by stock analysts at Cantor Fitzgerald from $315.00 to $300.00 in a research note issued on Friday,Benzinga reports.

On Friday, Cantor Fitzgerald initiated coverage on Protara Therapeutics (NASDAQ:TARA) with an Overweight rating, indicating a positive outlook for the biopharmaceutical company’s stock.

Exagen Inc. (NASDAQ:XGN – Free Report) – Stock analysts at Cantor Fitzgerald increased their FY2024 EPS estimates for Exagen in a research note issued to investors on Monday, March 10th.

In a report released yesterday, Andres Sheppard from Cantor Fitzgerald initiated coverage with a Buy rating on Eve Holding (EVEX – Research Report) and a price target of $5.00. The company’s ...